CN114146118B - External preparation for treating herpes zoster and preparation method thereof - Google Patents
External preparation for treating herpes zoster and preparation method thereof Download PDFInfo
- Publication number
- CN114146118B CN114146118B CN202111546532.1A CN202111546532A CN114146118B CN 114146118 B CN114146118 B CN 114146118B CN 202111546532 A CN202111546532 A CN 202111546532A CN 114146118 B CN114146118 B CN 114146118B
- Authority
- CN
- China
- Prior art keywords
- parts
- sesame oil
- herpes zoster
- external preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 53
- 239000008159 sesame oil Substances 0.000 claims abstract description 84
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 84
- 235000013871 bee wax Nutrition 0.000 claims abstract description 34
- 239000012166 beeswax Substances 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 30
- 241000202726 Bupleurum Species 0.000 claims abstract description 22
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 22
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 22
- 241000219784 Sophora Species 0.000 claims abstract description 22
- 238000010438 heat treatment Methods 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- 241000189144 Sedum lineare Species 0.000 claims description 16
- 244000046101 Sophora japonica Species 0.000 claims description 15
- 235000010586 Sophora japonica Nutrition 0.000 claims description 15
- 241000270295 Serpentes Species 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 239000007766 cera flava Substances 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 39
- 239000003814 drug Substances 0.000 abstract description 34
- 210000004185 liver Anatomy 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 15
- 231100000331 toxic Toxicity 0.000 abstract description 12
- 230000002588 toxic effect Effects 0.000 abstract description 12
- 239000003053 toxin Substances 0.000 abstract description 11
- 231100000765 toxin Toxicity 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 241000218228 Humulus Species 0.000 description 17
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000218229 Humulus japonicus Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241001398492 Sophora moorcroftiana Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The application provides an external preparation for treating herpes zoster and a preparation method thereof, and relates to the technical field of pharmacy. An external preparation for treating herpes zoster comprises the following raw materials in parts by weight: 5-30 parts of scandent hop, 1-5 parts of bupleurum, 5-15 parts of perfoliate knotweed herb, 5-10 parts of subprostrate sophora, 30-50 parts of sesame oil and 2-4 parts of beeswax. The formula of the application is coordinated properly, the scandent hop, the perfoliate knotweed herb, the subprostrate sophora, the sesame oil and the beeswax can play a role in clearing away heat and toxic materials, and can be used for treating the symptoms caused by damp heat or toxin; the bupleurum root has the effects of clearing liver fire and soothing liver and regulating qi, and is used for symptoms caused by exuberance of liver fire. The preparation integrates the drug properties of the medicines, and can jointly play the roles of eliminating dampness and removing heat, removing toxin, ventilating and activating blood, reducing pathogenic fire and soothing liver so as to radically treat the herpes zoster. In addition, the medicines and sesame oil are mixed and smeared on the affected part, the effective components can be absorbed rapidly and directly reach the focus, and the pain relieving effect is achieved.
Description
Technical Field
The application relates to the technical field of pharmacy, in particular to an external preparation for treating herpes zoster and a preparation method thereof.
Background
Shingles is the most common type of herpes, a skin infection caused by infection with varicella-zoster virus. The traditional Chinese medicine composition mainly shows long varicella among children, but the herpes zoster in middle-aged and elderly people has highest prevalence, has no obvious skin damage, but has serious neuralgia, viruses spread rapidly along the route of nerve travel, the herpes zoster has highest prevalence in spring and autumn, and the herpes zoster is mainly caused by the reduction of self resistance and the like.
The incidence of shingles is reported to be between 1.4 and 4.8% of the population, with about 20% of patients experiencing neuropathic pain. Elderly people over 50 years old are the main group of postherpetic neuralgia, accounting for about 75% of the affected people. In North America and European areas, more than 95% of the young adults are VZV seropositive and therefore at risk for shingles, with an annual incidence of shingles of about 3.4/1000; the prevalence of herpes zoster increases dramatically in people over 50 years old, reaching approximately 11/1000 in the 90 year old group. The disease is a pain problem in the medical community at present and is a potential killer for the health of middle-aged and elderly people.
Postherpetic neuralgia (Postherpetic neuralgia, PHN) is the most common chronic complication of shingles, and is also the most common post-infection neuralgia type. Postherpetic neuralgia is a compound neuropathic pain, which is a direct result of sustained injury to peripheral nerves during the invasive phase of shingles, and pathological injury to nerve tissue from the skin to the spinal cord is observed during the acute phase of shingles. The sustained spontaneous pain, light tenderness and paresthesia occurring at the primary herpetic site after healing of the herpetic skin is clinically considered, and the patients lasting for more than 1 month are called postherpetic neuralgia, and the postherpetic neuralgia is manifested by local paroxysmal or sustained intense intractable pain, such as causalgia, stinging pain, jumping pain, knife cutting pain, lightning pain, tearing pain, friction pain, insect bite pain, tightening pain, itching pain and the like, the patients have hyperalgesia and allodynia, the pain can be caused by wind blowing and light touch, and the pain can last for weeks, months or even years, seriously influence the life quality and physical and mental health of the patients, and can cause mental symptoms such as sleep disorder, anxiety depression and the like. It is reported that 9-18% of patients with shingles develop PHN, and that the occurrence of PHN is age-dependent: the incidence rate also increases with age, and the incidence rate of the age group of people older than 60 years of age is obviously increased.
Postherpetic neuralgia mainly includes three pain types: 1. irritation tenderness, a clinical manifestation characterized by hypersensitivity to pain, can produce intense intolerable pain by gentle touch; 2. arthralgia type pain, the clinical manifestations are characterized by superficial hypoesthesia and pain sensitivity, and the tenderness is obvious; 3. the central integrated pain type can clinically have the two types of manifestations, and is characterized by secondary sensitization abnormality of the central, and a patient visually depicts pain as fire-like pain, tearing-like pain, needling-like pain, knife-cutting-like pain, lightning-like pain, rope binding-like tightening pain and the like when in treatment.
The Chinese medicine of the herpes zoster is called as "herpes zoster" or "herpes zoster" and mainly refers to the fact that damp-heat fire toxin is generated on the skin and qi stagnation and blood stasis, and the key point of the pathogenesis is "toxin". The clinical manifestations are mainly pain and skin changes, so how to relieve pain faster is very important and urgent.
The causative agent is the only host of varicella-zoster virus, the virus enters blood through respiratory mucosa to form viremia, varicella or recessive infection occurs, and the virus can be hidden in spinal cord rear root ganglion or cranial nerve sensory ganglion for a long time. When the body is subjected to a stimulus (such as trauma, fatigue, malignancy, weakness after illness, etc.) that results in reduced body resistance, latent viruses are activated and replicate in the skin down the sensory nerve axis to the area innervated by the nerve to create blisters, while the affected nerve is inflamed, necrotized, and neuralgia is created.
At present, western medicines are adopted for pain relieving, nerve nourishing and antiviral treatment for treating the herpes zoster, but the western medicines have the defects of large side effect, poor pain relieving effect, inaccurate antiviral curative effect and discomfort caused by adverse reactions to the body. Therefore, there is an urgent need for a formulation that has a good therapeutic effect on shingles and can be radically cured.
Disclosure of Invention
The application aims to provide an external preparation for treating herpes zoster, which has the advantages of good treatment effect and capability of radically treating the herpes zoster.
It is another object of the present application to provide a method for preparing an external preparation for treating herpes zoster, to obtain the external preparation.
The application solves the technical problems by adopting the following technical scheme.
In one aspect, the embodiment of the application provides an external preparation for treating herpes zoster, which comprises the following raw materials in parts by weight: 5-30 parts of scandent hop, 1-5 parts of bupleurum, 5-15 parts of perfoliate knotweed herb, 5-10 parts of subprostrate sophora, 30-50 parts of sesame oil and 2-4 parts of beeswax.
In another aspect, the embodiment of the application provides a preparation method of an external preparation for treating herpes zoster, which comprises the following steps:
crushing the raw materials except sesame oil and beeswax into fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, uniformly mixing, soaking, and heating again to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
The applicant considers that the herpes zoster is caused by emotional internal injury and fire transformation caused by excessive liver fire and damp-heat internal accumulation, is induced by toxic pathogen, and further causes the toxic pathogen to transform fire, promote liver fire generation, and is combined with damp-heat to accumulate in the body, so that qi and blood are not smooth, and further qi stagnation and blood stasis, and blockage of channels and collaterals is caused on the body surface, so that pain is severe, the course of the disease is prolonged, and the symptom appears as herpes zoster.
Compared with the prior art, the embodiment of the application has at least the following advantages or beneficial effects:
the formula of the application is coordinated properly, the scandent hop, the perfoliate knotweed herb, the subprostrate sophora, the sesame oil and the beeswax can play a role in clearing away heat and toxic materials, and can be used for treating the symptoms caused by damp heat or toxin; the bupleurum root has the effects of clearing liver fire and soothing liver and regulating qi, and is used for symptoms caused by exuberance of liver fire. The preparation integrates the drug properties of the medicines, and can jointly play the roles of eliminating dampness and removing heat, removing toxin, ventilating and activating blood, reducing pathogenic fire and soothing liver so as to radically treat the herpes zoster. In addition, the medicines and the sesame oil are mixed and smeared on the affected part, the effective components can be absorbed rapidly and directly reach the focus, the analgesic effect is achieved, the oily ointment generates a layer of protective film on the skin, the external environment is isolated, the wound surface is protected from being polluted, and therefore the effects of preventing infection and promoting healing are achieved.
The application breaks the medicine into powder, is convenient for the medicine effect to be exerted in the sesame oil, and is soaked, so that the medicine effect is uniform, and the medicine effect and the sesame oil are heated, so that on one hand, sterilization can be realized, and on the other hand, the effective components can be promoted to volatilize in the sesame oil, thereby being convenient for the preparation to have good medicine effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
It should be noted that, without conflict, the embodiments of the present application and features of the embodiments may be combined with each other. The present application will be described in detail with reference to specific examples.
Humulus scandens (L.) kuh: pungent in flavor and flat in nature. Enter liver and large intestine meridians. Has effects of clearing heat and detoxicating, cooling blood and stopping bleeding. Can be used for treating dysentery, diarrhea, hemoptysis, hematuria, hematochezia, metrorrhagia, sore, furuncle, and carbuncle.
Bupleurum root: bitter taste and slightly cold nature. It enters liver and gallbladder meridians. Has effects of relieving exterior and interior syndrome, dispersing stagnated liver qi, and elevating yang. Can be used for treating common cold, fever, distending pain in chest and hypochondrium, menoxenia, prolapse of sub-organ, and rectocele.
And (3) perfecting plate return: sour taste and cool nature. Has effects of clearing heat and detoxicating, promoting urination and relieving swelling. Can be used for treating upper respiratory tract infection, tracheitis, pertussis, acute tonsillitis, enteritis, dysentery, nephritis and edema; it is indicated for herpes zoster, eczema, carbuncle, furuncle, swelling and snake bite.
Sedum lineare L: sweet in flavor and cold in nature. Has effects of clearing heat, detumescence and detoxification. For sore throat, carbuncle, furuncle, erysipelas, scald, snake bite, jaundice and dysentery.
Radix Sophorae Tonkinensis: bitter taste and cold nature; is toxic. Enter lung and stomach meridians. Has effects of clearing heat and detoxicating, detumescence and relieving sore throat. Can be used for treating toxic fire accumulation, laryngopharynx swelling and pain, and gingival swelling and pain.
Snake slough: salty and sweet in taste, and neutral in nature. Enter liver meridian. Has effects in dispelling pathogenic wind, arresting convulsion, removing toxic materials, and removing nebula. Can be used for treating infantile convulsion, nebula, obstruction of qi in the throat, furuncle, and skin pruritus.
Sophora japonica Makino: cold nature and bitter taste. Has antiinflammatory and toxic materials removing effects. For jaundice due to damp-heat and diphtheria.
Sesame oil: sweet in flavor and cool in nature. Has effects in moistening dryness, relieving constipation, removing toxic materials, and promoting granulation. Is used for treating constipation due to intestinal dryness, ascariasis, food stagnation, abdominal pain, sore, ulcer, scabies, and chapped skin. The sesame oil contains abundant vitamin E, has the functions of promoting cell division and delaying aging, and also contains about 40% of unsaturated fatty acids such as linoleic acid, palmitic acid and the like, and is easy to be decomposed, absorbed and utilized by human bodies.
Beeswax: sweet and light in taste and neutral in nature; enter spleen, stomach and large intestine meridians. Has effects in removing toxic materials, promoting granulation, relieving dysentery, stopping bleeding, and relieving pain. For carbuncles, ulcers, diarrhea, seminal emission, leukorrhagia, fetal movement of pregnancy, bleeding, and acute heart pain.
The application provides an external preparation for treating herpes zoster, which comprises the following raw materials in parts by weight: 5-30 parts of scandent hop, 1-5 parts of bupleurum, 5-15 parts of perfoliate knotweed herb, 5-10 parts of subprostrate sophora, 30-50 parts of sesame oil and 2-4 parts of beeswax.
The formula of the application is coordinated properly, the scandent hop, the perfoliate knotweed herb, the subprostrate sophora, the sesame oil and the beeswax can play a role in clearing away heat and toxic materials, and can be used for treating the symptoms caused by damp heat or toxin; the bupleurum root has the effects of clearing liver fire and soothing liver and regulating qi, and is used for symptoms caused by exuberance of liver fire. The preparation integrates the drug properties of the medicines, and can jointly play the roles of eliminating dampness and removing heat, removing toxin, ventilating and activating blood, reducing pathogenic fire and soothing liver so as to radically treat the herpes zoster. In addition, the medicines and the sesame oil are mixed and smeared on the affected part, the effective components can be absorbed rapidly and directly reach the focus, the analgesic effect is achieved, the oily ointment generates a layer of protective film on the skin, the external environment is isolated, the wound surface is protected from being polluted, and therefore the effects of preventing infection and promoting healing are achieved.
In some embodiments of the present application, the external preparation comprises the following raw materials in parts by weight: 8 parts of scandent hop, 2 parts of bupleurum, 7 parts of subprostrate sophora, 8 parts of perfoliate knotweed herb, 35 parts of sesame oil and 3 parts of beeswax.
In some embodiments of the present application, the external preparation comprises the following raw materials in parts by weight: 20 parts of scandent hop, 3 parts of bupleurum, 10 parts of perfoliate knotweed herb, 8 parts of subprostrate sophora, 40 parts of sesame oil and 3 parts of beeswax.
In some embodiments of the present application, the external preparation further comprises the following raw materials in parts by weight: 1-3 parts of sophora moorcroftiana, 5-10 parts of sedum lineare and 1-3 parts of snake slough. The Chinese scholartree, the sedum lineare and the periostracum cicada are used for synergistic effect with the above medicines, so that the medicine effect can be enhanced, the treatment effect of the herpes zoster is better, and the snake slough can be applied to the medicines to dispel the evil in the liver, enhance the effects of eliminating dampness and heat, removing toxin evil, ventilating and activating blood and reducing pathogenic fire and soothing the liver.
In some embodiments of the present application, the external preparation comprises the following raw materials in parts by weight: 8 parts of scandent hop, 2 parts of bupleurum, 8 parts of perfoliate knotweed herb, 7 parts of sedum lineare, 7 parts of subprostrate sophora, 2 parts of snake slough, 2 parts of sophora japonica, 35 parts of sesame oil and 3 parts of beeswax.
In some embodiments of the present application, the external preparation comprises the following raw materials in parts by weight: 12 parts of scandent hop, 3 parts of bupleurum, 10 parts of perfoliate knotweed herb, 8 parts of sedum lineare, 8 parts of subprostrate sophora, 2 parts of snake slough, 2 parts of sophora japonica, 40 parts of sesame oil and 3 parts of beeswax.
The application also provides a preparation method of the external preparation for treating herpes zoster, which comprises the following steps:
crushing the raw materials except sesame oil and beeswax into fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, uniformly mixing, soaking, and heating again to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
The application breaks the medicine into powder, is convenient for the medicine effect to be exerted in the sesame oil, and is soaked, so that the medicine effect is uniform, and the medicine effect and the sesame oil are heated, so that on one hand, sterilization can be realized, and on the other hand, the effective components can be promoted to volatilize in the sesame oil, thereby being convenient for the preparation to have good medicine effect.
In some embodiments of the application, the fines are 100-200 mesh in size. Crushing to this size allows better penetration of the drug into the sesame oil.
In some embodiments of the application, the above-described impregnation time is 24-48 hours. The fine powder can be soaked by sesame oil by full soaking, so that the subsequent drug effect can be conveniently permeated into the sesame oil.
In some embodiments of the application, the mixture is heated at a temperature of 115-130 ℃ for a period of 15-30 minutes.
The features and capabilities of the present application are described in further detail below in connection with the examples.
Example 1
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 50g of scandent hop, 10g of bupleurum, 50g of subprostrate sophora, 50g of perfoliate knotweed herb, 300g of sesame oil and 20g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 100-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 24h, and heating at 115 ℃ for 15min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 2
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 80g of scandent hop, 20g of bupleurum, 70g of subprostrate sophora, 80g of perfoliate knotweed herb, 350g of sesame oil and 30g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 150-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 36h, and heating at 125 ℃ for 25min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 3
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 200g of scandent hop, 30g of bupleurum, 100g of perfoliate knotweed herb, 80g of subprostrate sophora, 400g of sesame oil and 30g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 150-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 36h, and heating at 125 ℃ for 25min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 4
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 300g of scandent hop, 50g of bupleurum, 150g of perfoliate knotweed herb, 100g of subprostrate sophora, 500g of sesame oil and 40g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 200-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 48h, and heating at 130deg.C for 30min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 5
This embodiment differs from embodiment 1 in that: further comprises Sophora japonica, sedum lineare and periostracum Serpentis.
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 50g of scandent hop, 10g of bupleurum, 50g of subprostrate sophora, 50g of perfoliate knotweed herb, 300g of sesame oil, 20g of beeswax, 10g of sophora japonica, 50g of sedum lineare and 10g of snake slough.
Crushing the raw materials except sesame oil and beeswax into 100-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 24h, and heating at 115 ℃ for 15min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 6
This embodiment differs from embodiment 2 in that: further comprises Sophora japonica, sedum lineare and periostracum Serpentis.
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 80g of scandent hop, 20g of bupleurum, 80g of perfoliate knotweed herb, 70g of sedum lineare, 70g of subprostrate sophora, 20g of snake slough, 20g of sophora japonica, 350g of sesame oil and 30g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 150-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 36h, and heating at 125 ℃ for 25min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 7
This embodiment differs from embodiment 3 in that: further comprises Sophora japonica, sedum lineare and periostracum Serpentis.
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 120g of scandent hop, 30g of bupleurum, 100g of perfoliate knotweed herb, 80g of sedum lineare, 80g of subprostrate sophora, 20g of snake slough, 20g of sophora japonica, 400g of sesame oil and 30g of beeswax.
Crushing the raw materials except sesame oil and beeswax into 150-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 36h, and heating at 125 ℃ for 25min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Example 8
This embodiment differs from embodiment 4 in that: further comprises Sophora japonica, sedum lineare and periostracum Serpentis.
A preparation method of an external preparation for treating herpes zoster comprises the following steps:
raw materials: 300g of scandent hop, 50g of bupleurum, 150g of perfoliate knotweed, 100g of subprostrate sophora, 500g of sesame oil, 40g of beeswax, 30g of sophora japonica, 100g of sedum lineare and 30g of snake slough.
Crushing the raw materials except sesame oil and beeswax into 200-mesh fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, mixing uniformly, soaking for 48h, and heating at 130deg.C for 30min to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
Experimental example
180 patients with herpes zoster were selected and randomly divided into 9 groups of 20 persons, 1-8 groups being treatment groups, and treated with the external preparations prepared in examples 1-8, respectively, 9 groups being control groups, and treated with commercially available therapeutic agents, and evaluated after 10 days and 20 days, and the results are shown in tables 1-2.
Case criteria: unlimited sex, age and course of disease; excluding pregnant and lactating women, allergic system or allergic patients to the external preparation, including patients with inflammatory heart, liver, kidney and hematopoietic system diseases, hypoimmunity, mental diseases, malignant tumor late stage and AIDS patients.
The treatment group is coated with the external preparation locally at the skin injury part or the obvious pain part of the surrounding tissues, and the dressing is changed 3 times a day in the morning, in the middle and at the evening.
The control group was orally administered acyclovir tablets 3 times daily, 2 tablets each time, once every 2 hours, and acyclovir ointment was topically applied.
Evaluation criteria: efficacy assessment was performed according to the criteria in dermatology.
The effect is shown: the rash completely subsides or the subsides range exceeds 90 percent, and the pain is not caused;
the method is effective: the resolution range of the rash is 76-90%, and the pain feeling is obviously improved;
improvement: the resolution range of the rash is 50% -76%, and the pain feeling is improved;
invalidation: the rash resolved less than 50% and the pain was unchanged or aggravated.
Total effective rate= (effective + improvement)/total case number x 100%.
TABLE 1
TABLE 2
According to Table 1, it can be seen that the treatment effect of groups 1 to 8 is significantly better than that of group 9, and the number of significant effects is significantly greater. Comparing the 1-4 groups with the 5-8 groups, it can be seen that the 5-8 groups have better therapeutic effects than the 1-4 groups.
In conclusion, the formula of the application is coordinated properly, the scandent hop, the perfoliate knotweed herb, the subprostrate sophora, the sesame oil and the beeswax can play a role in clearing away heat and toxic materials, and can be used for treating the symptoms caused by damp heat or pathogenic toxin; the bupleurum root has the effects of clearing liver fire and soothing liver and regulating qi, and is used for symptoms caused by exuberance of liver fire. The preparation integrates the drug properties of the medicines, and can jointly play the roles of eliminating dampness and removing heat, removing toxin, ventilating and activating blood, reducing pathogenic fire and soothing liver so as to radically treat the herpes zoster. In addition, the medicines and the sesame oil are mixed and smeared on the affected part, the effective components can be absorbed rapidly and directly reach the focus, the analgesic effect is achieved, the oily ointment generates a layer of protective film on the skin, the external environment is isolated, the wound surface is protected from being polluted, and therefore the effects of preventing infection and promoting healing are achieved.
The application breaks the medicine into powder, is convenient for the medicine effect to be exerted in the sesame oil, and is soaked, so that the medicine effect is uniform, and the medicine effect and the sesame oil are heated, so that on one hand, sterilization can be realized, and on the other hand, the effective components can be promoted to volatilize in the sesame oil, thereby being convenient for the preparation to have good medicine effect.
The embodiments described above are some, but not all embodiments of the application. The detailed description of the embodiments of the application is not intended to limit the scope of the application, as claimed, but is merely representative of selected embodiments of the application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
Claims (6)
1. An external preparation for treating herpes zoster is characterized by being prepared from the following raw materials in parts by weight: 5-30 parts of scandent hop, 1-5 parts of radix bupleuri, 5-15 parts of perfoliate knotweed herb, 5-10 parts of subprostrate sophora, 30-50 parts of sesame oil, 2-4 parts of beeswax, 1-3 parts of sophora japonica, 5-10 parts of sedum lineare and 1-3 parts of snake slough;
the preparation method of the external preparation for treating herpes zoster comprises the following steps:
crushing the raw materials except sesame oil and beeswax into fine powder;
heating sesame oil to boil the sesame oil, stopping heating, pouring the fine powder into the sesame oil, uniformly mixing, soaking, and heating again to obtain a mixture;
heating Cera flava to melt, pouring into the mixture, and stirring to obtain the final product of the external preparation.
2. The external preparation for treating herpes zoster according to claim 1 is prepared from the following raw materials in parts by weight: 8 parts of scandent hop, 2 parts of bupleurum, 8 parts of perfoliate knotweed herb, 7 parts of sedum lineare, 7 parts of subprostrate sophora, 2 parts of snake slough, 2 parts of sophora japonica, 35 parts of sesame oil and 3 parts of beeswax.
3. The external preparation for treating herpes zoster according to claim 1 is prepared from the following raw materials in parts by weight: 12 parts of scandent hop, 3 parts of bupleurum, 10 parts of perfoliate knotweed herb, 8 parts of sedum lineare, 8 parts of subprostrate sophora, 2 parts of snake slough, 2 parts of sophora japonica, 40 parts of sesame oil and 3 parts of beeswax.
4. An external preparation for treating herpes zoster according to claim 1 wherein the fine powder is 100 to 200 mesh in size.
5. An external preparation for treating herpes zoster according to claim 1 characterised in that the infusion time is 24 to 48 hours.
6. An external preparation for treating herpes zoster according to claim 1 wherein the mixture is heated at a temperature of from 115 ℃ to 130 ℃ for a period of from 15 minutes to 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111546532.1A CN114146118B (en) | 2021-12-16 | 2021-12-16 | External preparation for treating herpes zoster and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111546532.1A CN114146118B (en) | 2021-12-16 | 2021-12-16 | External preparation for treating herpes zoster and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114146118A CN114146118A (en) | 2022-03-08 |
| CN114146118B true CN114146118B (en) | 2023-10-27 |
Family
ID=80451446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111546532.1A Active CN114146118B (en) | 2021-12-16 | 2021-12-16 | External preparation for treating herpes zoster and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114146118B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725501A (en) * | 2012-10-11 | 2014-04-16 | 杨海军 | Bushy sophora health care wine used for treating herpes zoster |
| CN107551048A (en) * | 2017-08-21 | 2018-01-09 | 高玉华 | A kind of Chinese medicinal plaster for treating herpes zoster |
| CN108355016A (en) * | 2018-05-25 | 2018-08-03 | 福州桂琨生物科技有限公司 | A kind of drug for treating herpes zoster |
| CN111920883A (en) * | 2020-10-10 | 2020-11-13 | 左艳红 | External preparation for treating herpes zoster and preparation method thereof |
-
2021
- 2021-12-16 CN CN202111546532.1A patent/CN114146118B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103725501A (en) * | 2012-10-11 | 2014-04-16 | 杨海军 | Bushy sophora health care wine used for treating herpes zoster |
| CN107551048A (en) * | 2017-08-21 | 2018-01-09 | 高玉华 | A kind of Chinese medicinal plaster for treating herpes zoster |
| CN108355016A (en) * | 2018-05-25 | 2018-08-03 | 福州桂琨生物科技有限公司 | A kind of drug for treating herpes zoster |
| CN111920883A (en) * | 2020-10-10 | 2020-11-13 | 左艳红 | External preparation for treating herpes zoster and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 带状疱疹;佚名;《广西中医药》;19811231(第S1期);第86页 带状疱疹处方1以及第87页 带状疱疹处方7 * |
| 蛇伤急救良药——季德胜蛇药片新用;张浩良;《中国中医急症》;19920615;第1卷(第01期);第45页左栏第1段以及第46页左栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114146118A (en) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432244B (en) | A kind of compositions with acne-removal function | |
| CN107050410B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| WO2023179779A1 (en) | Traditional chinese medicine composition for treating herpes zoster, and preparation method therefor | |
| CN114146118B (en) | External preparation for treating herpes zoster and preparation method thereof | |
| CN104491107A (en) | Traditional Chinese medicine preparation for treating burns and preparation method thereof | |
| CN104352616A (en) | Traditional Chinese medicine composition for treating sciatica and preparation method thereof | |
| CN116603012A (en) | Traditional Chinese medicine gel and preparation method and application thereof | |
| CN115957270A (en) | Externally applied medicine for treating herpes zoster | |
| US5106879A (en) | Treatment for inflammatory skin disease | |
| CN110721274B (en) | External antipruritic and preparation method thereof | |
| CN105031254B (en) | A kind of paste and preparation method thereof for treating dermatitis | |
| CN109394768B (en) | A kind of drug and preparation method thereof for treating eczema | |
| CN103316177B (en) | Ointment capable of promoting blood circulation to remove blood stasis, diminishing inflammation and relieving pain and preparation method thereof | |
| CN108721442B (en) | Traditional Chinese medicine composition and preparation for treating burns, scalds and diaper dermatitis and preparation method thereof | |
| CN110585286A (en) | A topical unguent for treating dermatoses, and its preparation method | |
| CN111920883A (en) | External preparation for treating herpes zoster and preparation method thereof | |
| CN110755508B (en) | Traditional Chinese medicine composition for relieving swelling and itching and preparation method thereof | |
| CN116585404B (en) | External traditional Chinese medicine composition for treating adult simple skin pruritus and preparation method thereof | |
| CN113144147B (en) | A topical Chinese medicinal composition for treating hypochondriac pain, and its preparation method | |
| CN116159086B (en) | Antibacterial, anti-inflammatory and antipruritic traditional Chinese medicine emulsifiable paste and preparation method thereof | |
| CN110585239B (en) | Plaster and preparation method and application thereof | |
| CN118236425A (en) | Traditional Chinese medicine composition and application thereof in preparation of perianal eczema treatment medicine | |
| CN112826831A (en) | Traditional Chinese medicine composition for treating skin diseases, preparation method and application | |
| CN116650582A (en) | Composition for treating herpes zoster and preparation method thereof | |
| CN111184806A (en) | Traditional Chinese medicine composition for treating chilblain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |